Telaprevir‐based treatment effects on hepatitis C virus in liver and blood
| Autor: | Christine M. Cervini, Min Jiang, Rositsa B. Dimova, Eileen Z. Zhang, Rishikesh Sawant, Marija Zeremski, Andrew H. Talal, Ann D. Kwong, Ira M. Jacobson, Marina Penney, Martyn Botfield, Ananthsrinivas Chakilam, James C. Sullivan |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Hepatitis C virus Biopsy Fine-Needle Gene Expression Hepacivirus Biology medicine.disease_cause Article Virus Telaprevir Young Adult chemistry.chemical_compound Internal medicine Drug Resistance Viral Gene expression medicine Humans Phylogeny Aged Models Statistical Hepatology Ribavirin Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Virology Treatment Outcome Liver Viral replication chemistry Immunology RNA Viral Female Oligopeptides medicine.drug |
| Zdroj: | Hepatology. 60:1826-1837 |
| ISSN: | 1527-3350 0270-9139 |
| Popis: | Understanding hepatitis C virus (HCV) replication has been limited by access to serial samples of liver, the primary site of viral replication. Our understanding of how HCV replicates and develops drug-resistant variants in the liver is limited. We studied 15 patients chronically infected with genotype 1 HCV treated with telaprevir (TVR)/pegylated-interferon alpha/ribavirin. Hepatic fine needle aspiration was performed before treatment and at hour 10, days 4 and 15, and week 8 after initiation of antiviral therapy. We measured viral kinetics, resistance patterns, TVR concentrations, and host transcription profiles. All patients completed all protocol-defined procedures that were generally well tolerated. First-phase HCV decline (baseline/treatment day 4) was significantly slower in liver than in plasma (slope plasma: −0.29; liver, −0.009; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text